Highlights ZyVersa Therapeutics, Inc.

Equities

ZVSA

US98987D3008

Real-time Estimate Cboe BZX Other stock markets 10:42:15 2024-06-06 EDT			5-day change	1st Jan Change
4.915 ^USD	+0.31%		+18.96%	-46.07%

05-15	ZyVersa Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
03-25	ZyVersa Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

ZyVersa Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-15	CI
ZyVersa Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-25	CI
ZyVersa Therapeutics, Inc. Announces IRB Approval of Phase 2A Clinical Trial Protocol to Evaluate Cholesterol Efflux Mediator VAR 200 in Patients with Diabetic Kidney Disease	03-18	CI
ZyVersa Therapeutics, Inc. Publishes New White Paper Detailing the Role of Inflammasomes and ASC Specks in Neurological Diseases, and Data Supporting Inflammasome ASC Inhibitor IC 100 as a Potential Therapeutic Option	02-22	CI
Jobs Data in Focus as Exchange-Traded Funds Advance, Equity Futures Mixed Pre-Bell Thursday	12-07	MT
ZyVersa Therapeutics, Inc. Announces Publication Showing AIM2 and NLRP3 Inflammasomes Promote Atherosclerosis in Diabetes, Supporting IC 100?s Rationale for Targeting ASC to Inhibit Multiple Inflammasome Pathways	12-06	CI
ZyVersa Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
ZyVersa Therapeutics, Inc. Announces Publication in Molecular Neurobiology Reinforcing Data Demonstrating that Inflammasome ASC Inhibitor IC 100 Attenuates Inflammatory Response Causing Neuronal Damage in Multiple Sclerosis Model, Potentially Providing Neuroprotection	11-01	CI
ZyVersa Therapeutics, Inc. Announces Research Published in the Peer-Reviewed Journal Diabetes Reinforcing IC 100's Rationale for Inhibiting ASC to Attenuate Damaging Inflammation Associated with Serious Conditions Such as Obesity-related Heart Disease	23-10-25	CI
ZyVersa Therapeutics, Inc. Announces New Peer-Reviewed Publication Reinforcing the Rationale for Inhibiting ASC Specks with IC 100 to Attenuate Spread of Inflammation into Surrounding Tissues	23-10-04	CI
Zyversa Therapeutics Announces Research Published in the Journal of Clinical Investigation Reinforcing Ic 100?s Rationale for Inhibiting ASC Specks to Attenuate Spread of Inflammation into Surrounding Tissues	23-09-22	CI
Zyversa Therapeutics, Inc. Announces Research Published in Frontiers in Immunology Reinforcing Ic 100'S Rationale for Inhibiting Multiple Inflammasomes to Control Inflammation in Various Inflammatory Diseases	23-09-12	CI
ZyVersa Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-21	CI
ZyVersa Therapeutics, Inc. Announces European Patent Granted for ZyVersa Therapeutics' Lead Asset, Cholesterol Efflux Mediatorâ„¢? VAR 200 for Use in Patients with Diabetic Nephropathy/Diabetic Kidney Disease	23-07-07	CI
ZyVersa Therapeutics, Inc. Announces Publication in Journal of the American Heart Association Linking NLRP3 Inflammasomes with Calcification in Arterial Disease	23-06-20	CI
European Patent Office to Grant Zyversa Therapeutics' Patent Application for Cholesterol Transport Mediator™? Var 200 for Use in Patients with Diabetic Nephropathy/Diabetic Kidney Disease	23-06-06	CI
ZyVersa Therapeutics, Inc. Announces Publication in Frontiers in Medicine Showing Direct Inflammasome Activation in Children with Juvenile Idiopathic Arthritis	23-05-25	CI
ZyVersa Therapeutics, Inc. Announces Changes to Board of Directors	23-05-19	CI
ZyVersa Therapeutics, Inc. Announces Article Published in Metabolism Pointing to Glomerular Cholesterol Accumulation as Key Factor Exacerbating Renal Injury and Dysfunction in Diabetic Kidney Disease	23-05-15	CI
ZyVersa Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights ZyVersa Therapeutics, Inc.

Equities

ZVSA

US98987D3008

Highlights

Filters